About pegaspargase
Pegylated antineoplastic enzyme
Used for
- Treats acute lymphoblastic leukemia as part of combination chemotherapy.
Usual adult dose
Commonly 2,000 IU/m² intravenously or intramuscularly every 14 days; schedules vary by treatment protocol.
Usual dose in children
Commonly 2,500 IU/m² intravenously or intramuscularly every 14 days; schedules vary by protocol and age.
Common side effects
- Allergic reactions, including severe anaphylaxis
- Pancreatitis
- Blood clots or bleeding
- Liver problems and abnormal blood sugar
Important warnings
- Can cause serious allergic reactions; monitoring is required during and after administration.
- May cause pancreatitis, severe liver injury, blood clots, or bleeding.
- Use only under specialist supervision as part of a chemotherapy regimen.
- Dose and route depend on treatment protocol and patient factors.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for at least three months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least three months after the last dose.
Interactions
- Other chemotherapy medicines may increase toxicity or alter treatment effects.
- Live vaccines may pose infection risk during chemotherapy.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.